CVS Study Question and answers verified to pass 2025/2026
1. RxConnect Entry Re- view
Step 1:Accept
the
Prescription
2. Step 2 :
Perform Data
Entry
3. Step 3:
Perform Data
1/
13
, P learly written) Date of birth (clearly written)
a Issue contact number
t Allergies to medication (if none, write NKA (no known allergies)
i Third Party information (if applicable)Cardholder's namePatient's
e relationship to cardholder
n Pertinent medical informationWhere appropriate (i.e., medical condition)
t Safety cap preferenceIt is the responsibility of the patient to request a non-
' safety capDo not assume all senior citizens want non-safety capsA
s patient's preference may become part of the patient's permanent file; it
is desirable to have this preference in writing but it is not a requirement
f Prescriber's name, address, and DEA
u number Prescription dated by the
l Prescriber
l Medication name, strength, quantity, and
directions Prescriber signature
n
a After the prescription is accepted, data entry is performed through
m insurance review while the patient is present at Drop-ott (except for
e Specialty prescriptions, where you will begin data entry and follow on-
screen prompts). Completing data entry through adjudication while the
a customer is present is critical as it helps to identify any issues, provides
n you an opportunity to resolve the issue, and provides a positive
d customer experience.
a During data entry, the insurance review and hardcopy scanning are
d also per- formed. Our goal is to identify and resolve any potential
d issues, including those related to inventory, that may arise during the fill
r process while the patient is present at Drop-ott. This allows us to resolve
e issues early in the process and provide the patient with a realistic
s expectation of when the prescription will be ready.
s
After completing the data entry and insurance is reviewed and scanned,
there is a data entry review that must take place. In QV, two statuses
(
will be shown: Data Entry Review and Production Review. Complete the
c
Data Entry Verification and DUR.
2/
13
1. RxConnect Entry Re- view
Step 1:Accept
the
Prescription
2. Step 2 :
Perform Data
Entry
3. Step 3:
Perform Data
1/
13
, P learly written) Date of birth (clearly written)
a Issue contact number
t Allergies to medication (if none, write NKA (no known allergies)
i Third Party information (if applicable)Cardholder's namePatient's
e relationship to cardholder
n Pertinent medical informationWhere appropriate (i.e., medical condition)
t Safety cap preferenceIt is the responsibility of the patient to request a non-
' safety capDo not assume all senior citizens want non-safety capsA
s patient's preference may become part of the patient's permanent file; it
is desirable to have this preference in writing but it is not a requirement
f Prescriber's name, address, and DEA
u number Prescription dated by the
l Prescriber
l Medication name, strength, quantity, and
directions Prescriber signature
n
a After the prescription is accepted, data entry is performed through
m insurance review while the patient is present at Drop-ott (except for
e Specialty prescriptions, where you will begin data entry and follow on-
screen prompts). Completing data entry through adjudication while the
a customer is present is critical as it helps to identify any issues, provides
n you an opportunity to resolve the issue, and provides a positive
d customer experience.
a During data entry, the insurance review and hardcopy scanning are
d also per- formed. Our goal is to identify and resolve any potential
d issues, including those related to inventory, that may arise during the fill
r process while the patient is present at Drop-ott. This allows us to resolve
e issues early in the process and provide the patient with a realistic
s expectation of when the prescription will be ready.
s
After completing the data entry and insurance is reviewed and scanned,
there is a data entry review that must take place. In QV, two statuses
(
will be shown: Data Entry Review and Production Review. Complete the
c
Data Entry Verification and DUR.
2/
13
